ASLN News and Press, ASLAN Pharmaceuticals Limited From 07/05/23

SAN MATEO, Calif. and SINGAPORE, July 05, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, will host a webcast to discuss the to...

SAN MATEO, Calif. and SINGAPORE, June 23, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the publication of da...

2023-06-22 11:21:31 ET ASLAN Pharmaceuticals ( NASDAQ: ASLN ) has licensed its atopic dermatitis candidate eblasakimab to Zenyaku Kogyo for Japanese rights. Terms call for ASLAN ( ASLN ) to receive $12M upfront, $3M in milestone payments from TREK-AD Phase 2b trial da...

ASLAN will receive up to $15 million in upfront and near-term payments and up to an additional $123.5 million based on development and commercial milestones plus tiered royalties on sales in percentages ranging up to low twenties Zenyaku Kogyo, a leading Japanese pharmaceutical company sp...

SAN MATEO, Calif. and SINGAPORE, June 01, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that management will present a company updat...

The Phase 2a, proof-of-concept study, called FAST-AA ( FArudodstat STudy in Alopecia Areata), will enroll approximately 60 adult patients in the US; interim topline readout is expected in 1Q 2024 Farudodstat is a potent, oral DHODH inhibitor with the potential to be a novel, f...

First study comparing blockade of the IL-4 receptor and IL-13 receptor, both components of the Type 2 receptor complex, presented in an oral late-breaking mini-symposium, revealed that IL-13Rα 1 blockade with eblasakimab may lead to more potent control of the Th2 inflam...

2023-04-28 07:40:37 ET ASLAN Pharmaceuticals press release ( NASDAQ: ASLN ): Q1 GAAP EPS of -$1.29 misses by $0.86 . US$57.5 million in cash and cash equivalents as of March 31, 2023; expected runway through at least the second quarter of 2024. For further detail...

Data readout for TREK-AD Phase 2b study of eblasakimab on track for early July 2023 Four abstracts on eblasakimab and farudodstat, including two late-breakers, to be presented at the 1 st International Societies of Investigative Dermatology ...

Late-breaking abstract on the differences between IL-13Rα1 and IL4R blockade on Type 2 and Type 1 signaling in atopic dermatitis (AD) accepted for oral presentation and late-breaking abstract on role of farudodstat in human model of alopecia areata accepted for poster p...